![Steven Lo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven Lo
Vorstandsvorsitzender bei
VAXART, INC.
Vermögen: 361 430 $ am 31.05.2026
Profil
Steven Lo is President, Chief Executive Officer & Director at Vaxart, Inc. since 2024.
Formerly, Mr. Lo was Chief Executive Officer & Director at Valitor, Inc. from 2022 to 2024; President, Chief Executive Officer & Director at Zosano Pharma Corp.
from 2019 to 2022; Chief Commercial Officer at Puma Biotechnology, Inc. from 2015 to 2019; Chief Commercial Officer & Senior Vice President at Corcept Therapeutics, Inc. from 2013 to 2015; Senior Director-Oncology Marketing at Genentech, Inc. from 1997 to 2010; Principal at Kaiser Permanente Washington Health Research Institute; and Member at Roche Group.
Education includes graduate studies at the University of Southern California and undergraduate studies at the University of California, Davis.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VAXART, INC. 0.23% | 26.05.2026 | 560’356 ( 0.23% ) | 361 430 $ | 31.05.2026 |
Aktive Positionen von Steven Lo
| Unternehmen | Position | Beginn |
|---|---|---|
| VAXART, INC. | Vorstandsvorsitzender | 18.03.2024 |
Ehemalige bekannte Positionen von Steven Lo
| Unternehmen | Position | Ende |
|---|---|---|
Valitor, Inc.
 Valitor, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel methods of modifying therapeutic proteins | Vorstandsvorsitzender | 01.03.2024 |
| ZOSANO PHARMA CORPORATION | Vorstandsvorsitzender | 01.08.2022 |
| PUMA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 04.10.2019 |
| CORCEPT THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 04.09.2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Ausbildung von Steven Lo
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
79
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Corcept Therapeutics, Inc.
 Corcept Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of drugs which treat severe metabolic, oncologic and neuropsychiatric disorders | Health Technology |
Kaiser Permanente Washington Health Research Institute
 Kaiser Permanente Washington Health Research Institute Hospital/Nursing ManagementHealth Services Provides healthcare plans and services | Health Services |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zosano Pharma Corp.
 Zosano Pharma Corp. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that specializes in the systemic administration of therapeutics | Health Technology |
Puma Biotechnology, Inc.
 Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Vaxart, Inc.
 Vaxart, Inc. BiotechnologyHealth Technology Develops vaccines | Health Technology |
Valitor, Inc.
Valitor, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel methods of modifying therapeutic proteins | Health Technology |
